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Abstract 
Background: Depression is a heterogeneous disorder with multiple aetiological pathways and 
multiple therapeutic targets. This study aims to determine whether atypical depression (AD) 
characterized by reversed neurovegetative symptoms is associated with a more pernicious 
course and a different sociodemographic, lifestyle, and comorbidity profile than nonatypical 
depression (nonAD).  
Methods: Among 157,366 adults who completed the UK Biobank Mental Health 
Questionnaire (MHQ), N=37,434 (24%) met the DSM-5 criteria for probable lifetime major 
depressive disorder (MDD) based on the Composite International Diagnostic Interview Short 
Form. Participants reporting both hypersomnia and weight gain were classified as AD cases 
(N=2,305), and the others as nonAD cases (N=35,129). Logistic regression analyses were 
conducted to examine differences between AD and nonAD in depression features, 
sociodemographic and lifestyle factors, lifetime adversities, psychiatric and physical 
comorbidities.  
Results: Persons with AD experienced an earlier age of depression onset, longer, more severe 
and recurrent episodes, and higher help-seeking rates than nonAD persons. AD was associated 
with female gender, unhealthy behaviours (smoking, social isolation, low physical activity), 
more lifetime deprivation and adversity, higher rates of comorbid psychiatric disorders, 
obesity, cardiovascular disease (CVD), and metabolic syndrome. Sensitivity analyses 
comparing AD persons with those having typical neurovegetative symptoms (hyposomnia and 
weight loss) revealed similar results.  
Conclusions: These findings highlight the clinical and public health significance of AD as a 
chronic form of depression, associated with high comorbidity and lifetime adversity. Our 
findings have implications for predicting depression course and comorbidities, guiding 
research on aetiological mechanisms, planning service use and informing therapeutic 
approaches.  
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Introduction 
Major depressive disorder (MDD) is a highly prevalent, burdensome, and 
heterogeneous mental health disorder. This heterogeneity presumably represents multiple 
causal pathways and consequently multiple therapeutic targets. The development of novel 
therapeutic agents would benefit from the identification of more homogeneous depression 
subtypes, which could be derived based on a triangulation of clinical phenotypes, risk factors 
and biology (Harald and Gordon, 2012). One such subtype is depression with atypical features.  
Atypical depression (AD) is an intriguing clinical phenomenon that has been 
recognised since the late 1950s and has evolved as a syndrome of varying definitions 
(Davidson and Thase, 2007, Lojko and Rybakowski, 2017). The Diagnostic and Statistical 
Manual of Mental Disorders 5th edition (DSM-5) criteria for AD requires mood reactivity and 
at least two of the following symptoms: increased appetite or weight gain, hypersomnia, leaden 
paralysis and interpersonal rejection sensitivity (American Psychiatric Association, 2013). 
Whereas most clinical studies adopt the DSM criteria for AD, community studies tend to 
classify AD based purely on reversed neurovegetative symptoms (i.e., hypersomnia and 
increased appetite/weight gain) (Lee et al., 2009, Levitan et al., 1997, Matza et al., 2003), for a 
number of reasons. First, reversed neurovegetative symptoms are easier to operationalise in 
epidemiological studies than other DSM criteria for atypicality. Second, several studies have 
questioned the evidential support for the role of mood reactivity and interpersonal rejection 
sensitivity in the diagnosis of atypical depression (Benazzi, 2002b, Parker and Thase, 2007). 
Third, reversed neurovegetative symptoms were found to be highly specific (90.5%), and have 
good positive predictive value (86.1%) for DSM-defined AD (Benazzi, 2002a). Fourth, 
research comparing AD based on reversed neurovegetative symptoms with AD based on the 
full DSM criteria found similar associations with a range of sociodemographic characteristics 
and comorbidities (Benazzi, 2002a). Lastly, AD based on reversed neurovegetative symptoms 
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may be more strongly associated with external validating characteristics of AD (e.g., gender, 
bipolar disorder, family history of mania) than other atypical symptoms of depression (Angst et 
al., 2006).   
There is growing interest in understanding the epidemiological, neurobiological, and 
genetic underpinnings of AD (Lojko and Rybakowski, 2017). Evidence from clinical and 
community-based studies suggest differences between AD and nonAD in sociodemographic 
factors, depression features, comorbidities, biomarkers, polygenic risk, and treatment response. 
Atypical depression is more strongly associated with female gender (Angst et al., 2007, Lee et 
al., 2009, Matza et al., 2003), younger age of depression onset, greater symptom severity, more 
depression episodes, greater functional impairment (Agosti and Stewart, 2001, Blanco et al., 
2012, Nierenberg et al., 1998, Stewart et al., 1993), and more adverse life events (Matza et al., 
2003, Withers et al., 2013). AD is also associated with higher rates of psychiatric comorbidity 
such as bipolar, anxiety, addictions, binge eating and psychotic disorders (Agosti and Stewart, 
2001, Angst et al., 2002, Blanco et al., 2012, Lee et al., 2009, McGinn et al., 2005), higher 
Body Mass Index (BMI) (Lasserre et al., 2014) as well as polygenic risk scores for BMI and 
triglycerides (Milaneschi et al., 2016), higher rates of metabolic syndrome, inflammation, and 
leptin dysregulation (Lamers et al., 2016a, Lamers et al., 2013, Milaneschi et al., 2017a), and 
greater heritability than nonAD (Lamers et al., 2016b). Existing evidence is limited by the use 
of different comparison groups across studies: non-atypical depression (i.e., depression without 
reversed neurovegetative symptoms) (e.g., Agosti and Stewart, 2001, Lee et al., 2009, Matza et 
al., 2003), typical depression with both neurovegetative symptoms (i.e., hyposomnia and 
reduced appetite and/or weight loss) (e.g., Blanco et al., 2012, Levitan et al., 1997) or just one 
neurovegetative symptom (i.e., appetite loss/weight loss) (e.g., Milaneschi et al., 2016), or 
melancholic depression (e.g., Angst et al., 2007, Lamers et al., 2016a).  
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An important proportion of persons who experience common mental health disorders 
such as depression do not receive clinical assessment or treatment. Conclusions from clinical 
studies on depression subtypes suffer from poor external validity and are not powered enough 
to consider multiple outcomes. Community-based psychiatric epidemiology studies are needed 
to help characterize depression phenotypes based on lifetime self-reported symptoms. Existing 
evidence from studies that examined atypical depression with reversed neurovegetative is 
limited by small sample size (Benazzi, 2002a, Levitan et al., 1997, Matza et al., 2003), a focus 
on current or recent rather than lifetime depression episodes (Lee et al., 2009), the use of 
different comparison groups, and data availability on a relatively limited number of 
comorbidities and correlates of atypical depression. 
The UK Biobank MHQ is one of the largest mental health surveys ever conducted 
among middle-aged and older adults (Davis et al., 2018). Given the diversity of mental health 
measures and linkages to UKB baseline assessments, this study offers the opportunity to 
replicate and extend evidence on the sociodemographic, clinical, lifestyle, and comorbidity 
profile of persons with lifetime AD characterized by reversed neurovegetative symptoms 
compared to those with nonAD, or those with typical neurovegetative symptoms. This 
foundational work could form the basis for exploring biomarker and genetic correlates of 
atypical depression in the UK Biobank, and could further guide intervention approaches. 
Method 
Subjects 
The UK Biobank is a well-characterized cohort of over half a million participants aged 
40 to 69 at baseline (2007-2010), providing the potential for a detailed examination of the 
interplay between genetic, biological, lifestyle, and environmental factors and the risk of 
physical and mental health disorders, which is further enhanced by planned follow-up 
assessments and linkages to routine healthcare records. A comprehensive description of the UK 
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Biobank cohort, study design, and assessments has been published elsewhere (Sudlow et al., 
2015). An online Mental Health Questionnaire (MHQ) was developed and implemented into 
the UK Biobank web questionnaire platform with the aim to identify mental health disorders 
either based on self-reported symptoms matching psychiatric diagnostic criteria or based on 
other self-reported psychiatric diagnosis (Davis et al., 2018). Participants who volunteered to 
take part in the study had higher socioeconomic status, healthier lifestyle and fewer health 
conditions than the general population (Davis et al., 2018, Fry et al., 2017). Out of 503,328 
participants who completed the baseline UK Biobank assessments, 339,092 (67.4%) 
participants received an email invitation to complete the MHQ, with 157,366 of those emailed 
(46.4%) responding by August 2017. Approximately 37,434 (23.8%) of those who completed 
the MHQ met the criteria for a lifetime diagnosis of MDD and were included in the current 
study.  
Measures 
Data were accessed through standard UKB procedures (access number 34553, Matthew 
Hotopf and collaborators) in July 2018. Case and control criteria for psychiatric disorders are 
presented in Supplementary Table 7 (Davis et al., 2018). All other variables were assessed 
using specific sets of questions and possible answers as detailed in Supplementary Table 6. All 
information on lifetime mental health symptoms, psychiatric diagnoses, and adverse life events 
(i.e., childhood, adulthood and catastrophic trauma) was collected during the MHQ 
assessments conducted in 2016-2017. Data on sociodemographic characteristics (i.e., age, 
gender, education, income, house ownership), lifestyle factors (i.e., smoking, physical activity, 
loneliness, social isolation), and physical comorbidities (i.e., longstanding illness, CVD, BMI, 
metabolic syndrome) were collected during the baseline UK Biobank assessments between 
2006 and 2010.  
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Lifetime MDD was assessed using the Composite International Diagnostic Interview 
Short Form (CIDI-SF) (Kessler and Ustun, 2004) and it required at least one core symptom of 
depression (i.e., persistent sadness or loss of interest) and at least four additional symptoms 
(i.e., tired or low energy, weight change, sleep change, trouble concentrating, feeling 
worthless, thinking about death), for a period of at least two weeks, representing a change from 
usual and associated with some or a lot of impairment. The CIDI-SF has been designed and 
shown to have good comparability with the full WHO Composite International Diagnostic 
Interview, although it shares with many screening tools a lack of specificity in community 
samples. Previous studies suggest that CIDI-SF has good sensitivity (89.6%) and specificity 
(93.9%), with 93.2% of respondents being classified as probable MDD cases on both the CIDI-
SF and the full CIDI interview when these instruments were administered as part of the same 
survey (Kessler and Ustun, 2004). However, independent validation studies reported that CIDI-
SF is highly sensitive but not very specific (i.e., identifies a high number of false positives), 
and recommended that CIDI-SF would be a useful general screening measure for depression, 
but not a highly accurate tool for prevalence estimates (Patten, 1997, Sunderland et al., 2011). 
Online CIDI-SF screening for recurrent MDD had a 81.8% validation rate by the SCID 
interview, whereas the validation rate for single episode MDD was 87.6% (Levinson et al., 
2017). The lifetime version of the CIDI-SF asked about symptoms experienced during the 
worst ever depression episode. Consistent with previous studies (Benazzi, 2002a, Blanco et al., 
2012, Lee et al., 2009), the presence of reversed neurovegetative symptoms was used to 
differentiate between AD and nonAD. Participants reporting both hypersomnia and weight 
gain were classified as AD cases (N=2,305), and the others classified as nonAD cases 
(N=35,129).  
Diagnostic criteria based on self-report questionnaires were also evaluated for 
generalised anxiety disorder, post-traumatic stress disorder (PTSD), and bipolar affective 
disorder (i.e., wider bipolar disorder, bipolar I disorder, and bipolar II disorder), as defined in 
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Supplementary Table 7. Of note, there is limited agreement about the definition of bipolar II 
disorder in MHQ. Whereas the DSM-IV criteria require symptoms present for minimum four 
days, the MHQ criteria require symptoms present for at least 1 week, so it could be predicted to 
miss some cases. Also, given that bipolar II disorder does not require disruption from 
symptoms, self-reported symptoms may reflect normal emotional experiences, resulting in an 
increased number of false positives (Davis et al., 2018). Other psychiatric comorbidities were 
defined by asking participants if they have ever been diagnosed with a psychiatric disorder by a 
mental health professional, including psychotic disorders (i.e., schizophrenia, other psychosis), 
anxiety disorders (i.e., panic attacks, agoraphobia, social phobia), obsessive compulsive 
disorder (OCD), eating disorders (i.e., anorexia nervosa, bulimia nervosa, binge-eating 
disorder), attention deficit hyperactivity disorder, autism spectrum disorder and personality 
disorders. Participants also self-reported any lifetime addiction (including substances and 
behaviours), substance dependence (including medication and illicit or recreational drugs), and 
alcohol dependence. They also reported a history of self-harm, with or without suicide intent 
(see Supplementary Table 6).  
Participants were classified as having metabolic syndrome if they had a waist 
circumference ≥ 102 cm or above for males and ≥ 88 cm for females, and a combination of any 
two of the following: 1) hypertension defined as a) average systolic blood pressure ≥ 140 over 
three assessment occasions and/or b) average diastolic blood pressure ≥ 90 over three 
assessment occasions, and/or c) hypertension medication prescription, and/or d) a clinical 
diagnosis of hypertension according to participant self-report; 2) diabetes defined as a) 
diabetes medication prescription; b) a clinical diagnosis of diabetes according to participant 
self-report; and 3) hypercholesterolemia defined as a) statins medication prescription; b) a 
clinical diagnosis of hypercholesterolemia according to participant self-report.  
Statistical Analysis 
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Univariate logistic regression models were conducted to examine differences between 
persons with AD (i.e., meeting the criteria for MDD + hypersomnia and weight gain) and 
persons with nonAD (i.e., meeting the criteria for MDD without hypersomnia and weight gain) 
in sociodemographic factors (i.e., age, gender, education, income, house ownership). 
Multivariable logistic regression models were used to examine differences between nonAD and 
AD in lifestyle factors, lifetime adversities, depression features, and comorbidities, controlling 
for age and gender, and then also for socioeconomic factors. Sensitivity analyses were 
conducted to compare persons with AD (as defined above) and those with typical vegetative 
symptoms (i.e., meeting the criteria for MDD + reporting weight loss, and either waking up too 
early or trouble falling asleep).  
Results 
Tetrachoric correlations between CIDI-SF depressive symptoms among persons with 
lifetime probable MDD are presented in Supplementary Table 5.  
Prevalence of depression subtypes and associations with sociodemographic factors 
The AD group (N=2,305) had a mean age of 59.8 years old and 75% were female, 
whereas the nonAD group (N=35,129) had a mean age of 62.4 years old and 68% were female. 
Persons with AD had lower income, and they were less likely to own a mortgage or the 
outright for their home than persons with nonAD (see Table 1).  
Depression course  
The mean age of depression onset was 31.9 in the AD group and 35.5 in the nonAD 
group. Compared to persons with nonAD those with AD experienced more severe, recurrent, 
and lengthy depression episodes. For instance, 24% of persons with AD experienced a 
depression episode lasting over 2 years compared to 13% of persons with nonAD; 39% of 
persons with AD experienced a severe depression episode compared to 14% of persons with 
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nonAD (i.e., depression was considered severe when all eight CIDI-SF symptoms were 
endorsed). Persons with AD were more likely to seek professional help for depression (see 
Table 2).  
Lifestyle factors and lifetime adversities 
Persons with atypical depression were more likely to be smokers, they reported higher 
rates of social isolation and loneliness, and lower rates of moderate physical activity. 
Moreover, they were more likely to experience a variety of adverse events over their life 
course, including emotional, physical and sexual abuse during childhood and adulthood, 
financial difficulties and catastrophic trauma (see Table 3). 
Psychiatric comorbidities 
Persons with AD were more likely to experience a probable lifetime psychiatric 
disorder of GAD, bipolar I and wider bipolar disorder (but not bipolar II), and they were more 
likely to meet the criteria for PTSD. Also, persons with AD were more likely to self-report a 
lifetime psychiatric diagnosis, including schizophrenia, agoraphobia, social phobia, panic 
attacks, OCD, autism spectrum disorders, ADHD, substance and alcohol dependence, 
personality disorders, and self-harm. The odds of binge eating disorder were 4.6 higher among 
persons with AD compared to those with nonAD. Persons with AD had lower rates of anorexia 
and similar rates of bulimia as those with nonAD (see Table 4).  
Physical comorbidities 
Persons with AD had higher odds of long-standing illness, CVD, and metabolic 
syndrome; they scored higher on each of the components of the metabolic syndrome: diabetes 
(OR = 2.32, 95% CI [1.94-2.78], hypertension (OR = 1.65, 95% CI [1.49-1.82] and 
hypercholesterolemia (OR = 1.49, 95% CI [1.30-1.71]. BMI scores were significantly higher 
among persons with AD (Mean = 30.7, SD = 5.9) compared to those with nonAD (Mean = 
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27.0, SD = 4.9), with a greater proportion of overweight and obese persons in the AD group 
(see Table 4).  
Sensitivity analyses  
 
All differences between AD and nonAD in depression features, sociodemographic and 
lifestyle factors, lifetime adversities, psychiatric and physical comorbidities remained 
statistically significant after accounting for socioeconomic status (i.e., income, house 
ownership, education), except for personality disorders and smoking status.  
The requirement of participants in the AD group to have two specific symptoms 
(hypersomnia and weight gain) may have resulted in the selection of a more severe sample, 
since severity in this definition is defined by number of symptoms. Therefore, we conducted a 
set of sensitivity analyses that compared persons with AD (i.e., hypersomnia and weight gain) 
with those meeting the criteria for depression with typical neurovegetative symptoms (i.e., 
weight loss and hyposomnia: waking too early or trouble falling asleep), thereby requiring two 
specific symptoms in both samples. Among depressed persons with typical neurovegetative 
symptoms 24% had severe depression, versus 39% of AD persons. These sensitivity analyses 
revealed a similar pattern of findings (in terms of direction, magnitude, and statistical 
significance of the effect) as the main analyses using nonAD as the comparison group, except 
for gender differences and personality disorder differences which were no longer statistically 
significant (see Supplementary Tables 1-4). 
Discussion 
This study ascertains AD based on reversed neurovegetative symptoms as a valid entity 
in a large community-based sample, and it informs on differences between AD and nonAD in 
terms of sociodemographic, lifestyle, and clinical characteristics, lifetime psychiatric and 
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physical comorbidities. These findings highlight the clinical and public health significance of 
the AD classifier.  
The previously reported prevalence of AD based on reversed neurovegetative 
symptoms was in the range of 11-16% (Horwath et al., 1992, Levitan et al., 1997). In our study 
about 6.5% (N=2305) of persons with MDD met the criteria for AD. Given that the UK 
Biobank sample is not representative for the general population (i.e., healthy volunteer effect) 
these results should not be interpreted as estimates of AD prevalence in the wider community, 
but rather as proportions within the sample. Building on prior evidence, our findings suggest 
that persons with AD have a younger age of depression onset (Blanco et al., 2012, Koyuncu et 
al., 2015, Matza et al., 2003, Novick et al., 2005, Thase, 2007), longer (Angst et al., 2002, 
Posternak and Zimmerman, 2002), more severe (Blanco et al., 2012, Novick et al., 2005), and 
recurrent episodes (Blanco et al., 2012, Koyuncu et al., 2015), and higher help seeking rates 
(Angst et al., 2006, Lee et al., 2009, Matza et al., 2003) compared to persons with nonAD. 
Consistent with previous evidence, we found that depression with atypical features was 
associated with female gender (Agosti and Stewart, 2001, Benazzi, 2002a, Blanco et al., 2012, 
Lee et al., 2009) and with unhealthier behaviours, such as reduced physical activity (Glaus et 
al., 2013), social isolation (Agosti and Stewart, 2001), and smoking. Previously, Koyuncu et 
al. (2015) found higher rates of social anxiety and avoidance among individual with AD 
features. These findings are not surprising given that hypersensitivity to criticism or rejection is 
a characteristic feature of AD which can lead individuals to avoid interpersonal activity and 
social situations. Consistent with prior reports (Blanco et al., 2012), we found that persons with 
AD were more likely to experience socio-economic disadvantage than persons with nonAD. 
Previously, childhood trauma, in the form of physical or sexual abuse, was associated with the 
reversed neurovegetative symptoms of AD (Matza et al., 2003). Our findings add to the 
existing literature by showing that AD is associated with a range of emotional, physical, 
sexual, financial and catastrophic adversities across the lifespan.  
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The diversity of mental health assessments in the MHQ offered the opportunity to 
examine associations between AD and a wide range of lifetime psychiatric comorbidities. Our 
findings on psychiatric comorbidities are consistent with a large community-based study on 
lifetime atypical depression conducted in the United States (Blanco et al., 2012). We found that 
persons with AD had higher rates of bipolar I and wider bipolar disorder than those with 
nonAD, but differences in bipolar II disorder were only marginally significant. An association 
between AD and bipolar I but not bipolar II was previously reported by Blanco et al. (2012), 
but most existing evidence supports a strong association between AD and bipolar II disorder 
(Agosti and Stewart, 2001, Akiskal and Benazzi, 2005, Angst et al., 2002, Benazzi, 2002a, Lee 
et al., 2009). The failure to replicate this finding in our study may be due to the arguable 
definition of bipolar II disorder in the MHQ (Davis et al., 2018) (see Supplementary Table 7). 
Our findings are consistent with prior evidence suggesting higher rates of anxiety disorders 
(i.e., generalised anxiety, panic attacks, social phobia, agoraphobia) (Angst et al., 2002, Blanco 
et al., 2012, Horwath et al., 1992, Koyuncu et al., 2015, Matza et al., 2003, Novick et al., 
2005, Sullivan et al., 1998), OCD (Perugi et al., 1998), psychotic disorders (Blanco et al., 
2012), binge eating (Angst et al., 2006, Angst et al., 2002), substance and alcohol dependence 
(Blanco et al., 2012), and personality disorders (McGinn et al., 2005) among persons with AD. 
Additionally, we found that persons with AD had higher rates of ADHD, autism, and self-
harm, but they were not more likely than persons with nonAD to self-harm with suicide intent. 
A study conducted in Hong Kong reported a trend for higher rates of suicidal ideation and 
suicidal attempt in AD (Lee et al., 2009).  
The association between MDD and obesity is supported by widespread evidence, 
including findings from a recent UK Biobank study (Ul-Haq et al., 2014). Emerging evidence 
suggests higher rates of obesity and metabolic syndrome among persons meeting the full 
DSM-IV criteria for atypical depression (Lasserre et al., 2014) and among those meeting only 
the hyperphagia and weight gain criteria (Lamers et al., 2013). Recent evidence also suggests a 
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genetic overlap between obesity and an AD subtype characterized by increased appetite and 
weight gain (Milaneschi et al., 2017b). We found that among persons with AD characterized 
by reversed neurovegetative symptoms 49% were obese (BMI ≥ 30) and 36% were overweight 
(BMI ≥ 25), whereas among nonAD persons 22% were obese and 39% were overweight. 
Biological theories propose that leptin dysregulation and inflammation underlie the association 
between obesity and atypical depression, whereas psychological theories suggest that the 
interpersonal rejection sensitivity that is characteristic to AD is accompanied by emotional 
dysregulation mechanisms and self-consolatory behaviours such as comfort eating (for a 
review see Lojko and Rybakowski, 2017). With regard to the association between atypical 
depression and CVD, prior evidence is mixed, with some findings suggesting a higher CVD 
incidence among AD persons with reversed neurovegetative symptoms (Case et al., 2018), 
whereas other reports support and association between atypical depression and cardiovascular 
risk factors but not CVD diagnosis (Niranjan et al., 2012). Our findings confirm higher rates of 
CVD among AD persons. It should be noted that information on physical comorbidities was 
collected during the UK Biobank baseline assessments conducted approximately seven years 
before the MHQ. The relation between depression and comorbidities such as obesity, 
metabolic syndrome and CVD is likely multifaceted and bidirectional. Given that our study 
focused on lifetime depression it was not possible to determine whether physical disorders 
occurred before or after the atypical depression episode, hence not allowing inferences about 
the direction of the effect.  
Finally, it is worth noting that the same pattern of results emerged when comparing 
persons with AD (hypersomnia and weight gain) with those reporting the opposite/typical 
neurovegetative symptoms (hyposomnia and weight loss), suggesting that the observed 
findings are not simply attributable to the selection of more severe depression cases in the AD 
group.  
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Strengths and limitations 
The current study based on the UK Biobank MHQ dataset provided a unique 
opportunity to identify differences between typical and atypical depression in illness course, 
sociodemographic and lifestyle factors, adverse life events and comorbidities in a large 
community sample of middle aged and older adults. However, there are also a number of 
limitations. First, the UK Biobank is not representative for the overall population as there is a 
degree of ‘healthy volunteer’ selection bias, with higher participation rates among females, 
older, better educated, less deprived, and healthier participants than the general population (Fry 
et al., 2017). Furthermore, participants who completed the MHQ have higher educational and 
occupational attainment, and lower rates of longstanding illness, disability and smoking than 
the overall UK Biobank cohort and the general population (Davis et al., 2018). It has been 
previously shown that non-response to MHQ is weakly related to depression status, with 
20.3% of the MHQ respondents versus 23.6% of the MHQ non-respondents reporting feeling 
depressed during the last two weeks preceding the baseline UKB assessment (conducted 
approximately 7 years before the MHQ), and 5.2% of the MHQ respondents versus 7.1% of the 
MHQ non-respondents reporting a lifetime medical diagnosis of depression during the baseline 
UK Biobank assessments (Davis et al., 2018). It was not possible to compare non-response 
rates between the AD and the nonAD group because baseline UK Biobank assessments did not 
include questions allowing a characterization of depression subtypes. It is possible that the 
healthy volunteer selection bias in the UK Biobank MHQ may have resulted in an 
underestimation of the prevalence of AD in our sample, given the higher depression severity 
among AD patients and the fact that severely depressed persons were less likely to complete 
the MHQ. Second, due to the cross-sectional nature of this study, our findings do not allow to 
determine whether life events and comorbidities occurred before, during or after the typical 
versus atypical depression episode. Moreover, it was not possible to determine whether 
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participants experienced lifetime fluctuations between typical and atypical depression episodes 
as suggested by previous reports (Angst et al., 2007, Levitan et al., 1997). Third, psychiatric 
conditions were assessed using self-reported symptoms and self-reported diagnosis, so they 
represent probable, rather than definitive, clinical diagnoses (Davis et al., 2018). CIDI-SF does 
not contain questions assessing appetite changes, but only weight changes. We had no specific 
cut-off points to quantify the weight gain or the number of hours of sleep per night during the 
worst depression episode. Therefore, we cannot exclude the possibility that self-reported 
symptoms may be subject to recall bias or may be affected by other medical conditions. 
Finally, our assessments did not capture other atypical symptoms such as leaden paralysis, 
interpersonal rejection sensitivity or mood reactivity. Nevertheless, our findings based on a 
definition of atypical depression characterized by reversed neurovegetative symptoms are 
remarkably consistent with prior evidence from both clinical and community-based studies.  
Conclusions and implications 
The symptom heterogeneity of depression, in conjunction with etiological and 
methodological heterogeneity, hinders progress in the diagnosis, prognosis and treatment of 
depression. A better characterization of the AD subtype in terms of symptom profile, clinical 
course, neurobiology and comorbidities could inform personalized medicine approaches (Korte 
et al., 2015). Our findings suggest that criteria such as early age of onset, chronicity, and 
recurrence should be considered as part of the clinical picture of AD. The pernicious course of 
AD and the high psychiatric comorbidity profile have important implications for health care 
utilization and costs. In clinical practice, focusing on the identification of atypical features 
could inform prognosis, and treatment planning. Future research should determine to what 
extent the early identification and treatment of atypical depression symptoms may prevent or 
delay the onset of physical comorbidities. Forthcoming availability of biomarker data in the 
UK Biobank will provide the opportunity to further examine metabolic and inflammatory 
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biomarkers in atypical depression. The high rate of obesity and metabolic syndrome among 
atypically depressed persons could have implications for treatment selection (i.e., 
antidepressant treatment that does not influence weight gain). Patients with different/opposite 
depression symptoms likely have different neurobiological disturbances and could benefit from 
better tailored therapeutic approaches. Although findings on differential treatment response are 
largely controversial (Harald and Gordon, 2012), recent evidence suggests larger treatment 
response to exercise in AD compared to nonAD (Rethorst et al., 2016), a superior effect of 
cognitive therapy compared to paroxetine treatment in reducing atypical-vegetative symptoms 
(Fournier et al., 2013), and the potential of pharmacotherapy and cognitive therapy 
continuation to reduce relapse rates among persons with AD (Jarrett et al., 2000). Clinical trials 
should further determine the effectiveness of lifestyle interventions and therapeutic agents 
targeting metabolic and inflammatory pathways in AD. This knowledge could inform 
treatment guidelines and facilitate a better management of persons with atypical symptoms of 
depression.  
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Table 1. Sociodemographic differences between persons with atypical depression and those  
with non-atypical depression 
  Atypical Depression  Non-Atypical Depression   
  N=2,305  N=35,129     
  
n % n % OR (95% CI) P value  
Age                 
  
45to54 
55to64      
65to74      
75Plus      
625 
1,051 
585  
44   
27.1 
45.6 
25.4 
1.9 
6,520 
13,758 
13,154 
1,697 
18.6 
39.2 
37.4 
4.8 
Ref 
0.79(0.72-0.88) 
0.46(0.41-0.52) 
0.27(0.20-0.37) 
P < 0.001 
P < 0.001 
P < 0.001 
P < 0.001 
Gender           
 
Female 
Male 
1,732 
573 
75.1 
24.9 
24,083 
11,046 
68.6 
31.4 
Ref 
0.95(0.94-0.96) 
 
P < 0.001 
Education None 
Other (vocational) 
Secondary school 
A level  
Degree 
113 
89 
705 
397 
974 
4.9 
3.9 
31.0 
17.4 
42.8 
2,040 
1,788 
10,006 
4,982 
15,965 
5.9 
5.1 
28.8 
14.3 
45.9 
Ref 
0.90(0.68-1.19) 
1.27(1.04-1.56) 
1.44(1.16-1.78) 
1.10(0.90-1.35) 
 
P = 0.46 
P < 0.05 
P < 0.01 
P = 0.34 
 
Income <£18,000 
£18,000-30,000  
£30,000-52,000 
£52,000-100,000 
>£100,000 
442 
511 
597 
457 
94 
21.0 
24.3 
28.4 
21.8 
4.5 
5,311 
7,642 
9,158 
7,823 
2,013 
16.6 
23.9 
28.7 
24.5 
6.3 
Ref 
0.80(0.70-0.92) 
0.78(0.69-0.89) 
0.70(0.61-0.80) 
0.56(0.45-0.71) 
 
  P < 0.01 
P < 0.001 
P < 0.001 
P < 0.001 
House 
ownership 
Rent social 
Rent private 
Own mortgage 
Own outright  
197 
120 
1,078 
839 
8.8 
5.4 
48.2 
37.6 
1,464 
1,124 
15,230 
16,562 
4.2 
3.3 
44.3 
48.2 
Ref 
0.79(0.62-1.01) 
0.53(0.45-0.62) 
0.38(0.32-0.44) 
 
   P = 0.06 
 P < 0.001 
P < 0.001 
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Table 2. Differences in depression age of onset, severity, recurrence, episode duration, and help seeking 
between persons with atypical depression and those with non-atypical depression 
 Atypical Depression  Non-Atypical Depression  
N=2,305  N=35,129     
 
n Mean (SD) n Mean (SD) OR (95% CI) P value  
Age depression onset 2,120 31.9(14.5) 32,793 35.5(14.5) 0.98 (0.98-0.99) P < 0.001 
 
n % n % OR (95% CI) P value  
Severe depression 910 39.5 5,043 14.4 2.80(2.46-3.20) P < 0.001 
Recurrent depression  1,583 74.9 19,604 58.1 2.03(1.84-2.25) P < 0.001 
Duration of worst episode       
<1 month 76 3.3 2,177 6.3 Ref  
1 to 3 months 436 19.0 9,394 26.9 1.31(1.02-1.68) P < 0.05 
3 to 6 months 440 19.2 7,101 20.4 1.70(1.32-2.17) P < 0.001 
6 to 12 months 434 18.9 6,681 19.2 1.78(1.39-2.28) P < 0.001 
1 to 2 years 352 15.4 4,976 14.3 2.00(1.55-2.58) P < 0.001 
>2 years 554 24.2 4,528 13.0 3.45(2.70-4.41) P < 0.001 
Help seeking for depression 2,076 90.1 28,440 80.9 2.04(1.78-2.36) P < 0.001 
Note: Models are adjusted for age and gender 
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Table 3. Differences in lifestyle factors and adverse life events between persons with atypical depression 
and those with non-atypical depression 
  Atypical Depression Non-Atypical Depression  
  N=2,305  N=35,129    
Lifestyle factors 
 
n % n % OR (95% CI) P value  
Smoking          
 
Never 
Ever 
 
1,117 
 
48.7 
 
16,448 
 
46,9 
Ref 
1.15(1.06-1.26) 
 
 
P < 0.01 
Social isolation     
 
No 
Yes 
 
293 
 
12.9 
 
3,534 
 
10.2 
Ref 
1.32(1.16-1.51) 
 
P < 0.001 
Loneliness No 
Yes 
 
223 
 
10.1 
 
2,144 
 
6.3 
Ref 
1.74(1.50-2.01) 
 
P < 0.001 
Moderate physical 
activity 
No 
Yes 
 
1,312 
 
56.9 
 
22,134 
 
63.0 
Ref 
0.80(0.74-0.88) 
 
P < 0.001 
Childhood adversities 
      
Felt loved  Yes 
No 
 
378 
 
16.5 
 
3,780 
 
10.8 
Ref 
1.61(1.43-1.80) 
 
P < 0.001 
Felt hated  No 
Yes 
 
645 
 
28.1 
 
6,229 
 
17.8 
Ref 
1.67(1.52-1.84) 
 
P < 0.001 
Physical abuse  No  
Yes 
 
449 
 
19.7 
 
4,660 
 
13.3 
Ref 
1.51(1.36-1.68) 
 
P < 0.001 
Sexual abuse No 
Yes 
 
251 
 
11.2 
 
2,508 
 
7.3 
Ref 
1.48(1.29-1.70) 
 
P < 0.001 
Had someone to take 
to doctor when 
needed as a child 
Yes 
No 
 
263 
 
11.5 
 
2,684 
 
 
7.7 
Ref 
1.57(1.37-1.80) 
 
P < 0.001 
Adulthood adversities       
Been in confiding 
relationship  
Yes 
No 
 
450 
 
19.9 
 
5,135 
 
14.9 
Ref 
1.40(1.26-1.57) 
 
P < 0.001 
 
Physical violence by 
partner 
No 
Yes 
 
394 
 
17.2 
 
4,050 
 
11.6 
Ref 
1.44(1.28-1.61) 
 
P < 0.001 
Belittlement by 
partner 
No  
Yes 
 
837 
 
36.5 
 
9,212 
 
26.3 
Ref 
1.48(1.36-1.62) 
 
P < 0.001 
Non-consensual 
sexual interference 
by partner 
No 
Yes 
 
201 
 
8.8 
 
1,862 
 
5.3 
Ref 
1.54(1.32-1.80) 
 
P < 0.001 
 
Unable to pay rent or 
mortgage 
No 
Yes 
 
317 
 
13.9 
 
3,196 
 
9.2 
Ref 
1.56(1.37-1.77) 
 
P < 0.001 
Catastrophic trauma No 
Yes 
 
1,562 
 
67.8 
 
20,604 
 
58.7 
Ref 
1.51(1.37-1.65) 
 
P < 0.001 
Note: Models are adjusted for age and gender. Catastrophic trauma is defined being attacked, mugged, robbed,  
exposed to violent crime, sexual assault, serious accidents, life-threatening illness, combat or war, violent death.  
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Table 4. Differences in psychiatric and physical comorbidities between persons with atypical depression 
and those with non-atypical depression 
 Atypical Depression  Non-Atypical Depression  
 N=2,305  N=35,129    
Probable psychiatric diagnoses based on self-reported symptoms 
 
 
n                %                     n                %                     OR (95% CI) P value  
Wider Bipolar  166 7.4 1,384 4 1.86(1.58-2.21) P < 0.001 
Bipolar 1 118 5.3 813 2.4 2.24(1.83-2.73) P < 0.001 
Bipolar 2 38 1.7 417 1.2 1.29(0.99-1.95) P = 0.06 
GAD 754 60.2 7,690 44.3 1.82(1.62-2.04) P < 0.001 
PTSD 717 31.3 5,656 16.2 2.21(2.01-2.42) P < 0.001 
Self-reported psychiatric diagnoses           
Schizophrenia 14 0.6 71 0.2 3.19(1.78-5.70) P < 0.001 
Other psychosis  50 2.2 378 1.1 1.99(1.47-2.69) P < 0.001 
Panic attacks 413 17.9 4,142 11.8 1.60(1.43-1.79) P < 0.001 
Agoraphobia  40 1.7 327 0.9 1.91(1.37-2.67) P < 0.001 
Social phobia 135 5.9 1,006 2.7 2.07(1.71-2.49) P < 0.001 
Any other phobia 83 3.6 728 2.1 1.77(1.41-2.24) P < 0.001 
OCD 75 3.3 493 1.4 2.19(1.71-2.81) P < 0.001 
Anorexia nervosa 18 0.8 450 1.3 0.52(0.32-0.84) P < 0.01 
Bulimia nervosa 24 1.0 251 0.7 1.13(0.74-1.72) P = 0.58 
Binge-eating 116 5.0 355 1.0 4.67(3.76-5.81) P < 0.001 
ADHD 10 0.4 54 0.2 2.86(1.44-5.65) P < 0.01 
Autism spectrum disorder 16 0.7 106 0.3 2.30(1.30-3.90) P < 0.01 
Personality disorder 27 1.2 243 0.7 1.60(1.07-2.39) P < 0.05 
Any addiction 360 16.3 3,712 10.9 1,56(1.38-1.75) P < 0.01 
Substance Dependence 232 10.7 2,235 6.4 1.65(1.43-1.91) P < 0.05 
Alcohol Dependence  61 2.7 501 1.4 2.00(1.52-2.63) P < 0.001 
Self-harm  385 16.8 3,855 11.0 1.46(1.30-1.64) P < 0.001 
Self-harm with suicidal 
intention 
219 59.5 2,152 58.0 1.15(0.92-1.44) P = 0.21 
Physical comorbidities  
      
Any long-standing illness 1,169 50.7 12,194 35.5 2.19(2.01-2.39) P < 0.001 
CVD 650 28.3 8,280 23.6  1.63 (1.48-1.80) P < 0.001 
Metabolic syndrome 194 8.4 1,656 4.7 2.39 (2.04-2.80) P < 0.001 
Body Mass Index 
Normal (< 18.5) 
 
334 
 
14.5 
 
13,386 
 
38.2 
 
Ref. 
 
Underweight (18.5–24.9) 
Overweight (25.0–29.9)  
Obese (>30) 
3 
834 
1,131 
0.1 
36.2 
49.1 
228 
13,658 
7,770 
       0.7 
     39.0 
22.2 
0.49(0.15-1.54) 
2.79(2.44-3.17) 
6.47(5.71-7.35) 
P = 0.22 
P < 0.001 
P <0.001 
Note: Models are adjusted for age and gender 
 
  
 
Supplementary Table 1. Sociodemographic differences between persons with atypical  
depression versus depression with typical neurovegetative symptoms 
  Atypical Depression  Typical Depression   
  N=2,305  N=12,660     
  
n % n % OR (95% CI) P value  
Age                 
  
45to54 
55to64      
65to74      
75Plus      
625 
1,051 
585 
44 
27.1 
45.6 
25.4 
1.9 
2,324 
5,002 
4,757 
577 
18.4 
39.5 
37.6 
4.6 
Ref 
0.78(0.70-0.87) 
0.45(0.40-0.51) 
0.28(0.21-0.39) 
 
P < 0.001 
P < 0.001 
P < 0.001 
Gender           
 
Female 
Male 
1,732 
573 
 
75.1 
24.9 
9,575 
3,085 
 
75.6 
24.4 
 
Ref 
1.03(0.92-1.14) 
 
P = 0.61 
Education None 
Other(vocational) 
Secondary school 
A level  
Degree 
113 
89 
705 
397 
974 
5.0 
3.9 
31.0 
17.4 
42.8 
794 
700 
3,895 
1,768 
5,378 
6.3 
5.6 
31.1 
14.1 
42.9 
Ref 
0.89(0.66-1.20) 
1.27(1.03-1.57) 
1.57(1.26-1.98) 
1.27(1.03-1.57) 
 
P = 0.45 
P < 0.01 
P < 0.001 
P < 0.05 
 
Income <£18,000 
£18,000-30,000  
£30,000-52,000 
£52,000-100,000 
>£100,000 
442 
511 
597 
457 
94 
21.0 
24.3 
28.4 
21.8 
4.5 
1,944 
2,798 
3,270 
2,709 
733 
17.0 
24.4 
28.6 
23.7 
6.4 
Ref 
0.80(0.69-0.92) 
0.80(0.70-0.92) 
0.74(0.64-0.85) 
0.56(0.44-0.71) 
 
P < 0.01 
P < 0.01 
P < 0.001 
P < 0.001 
House 
ownership 
Rent social 
Rent private 
Own mortgage 
Own outright  
197 
120 
1,078 
839 
8.8 
5.4 
48.3 
37.6 
474 
366 
5,483 
6,062 
3.8 
3.0 
44.3 
49.0 
Ref 
0.78(0.61-1.02) 
0.47(0.39-0.56) 
0.33(0.27-0.40) 
 
P = 0.07 
P < 0.001 
P < 0.001 
 
Note: Atypical depression is defined as meeting the DSM-V criteria for MDD and reporting 
symptoms of hypersomnia and weight gain; depression with typical neurovegetative symptoms is 
defined as meeting the DSM-V criteria for MDD and reporting symptoms of hyposomnia and weight 
loss. 
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Supplementary Table 2. Differences in depression age of onset, severity, recurrence, episode duration, 
and help seeking between persons with atypical depression versus depression with typical neurovegetative 
symptoms 
 Atypical Depression    Typical Depression   
N=2,305 N=12,660     
 N Mean (SD) N Mean (SD) OR (95% CI) P value  
Age depression onset 2,120 31.9(14.5) 12,051 36.1(14.1) 0.99 (0.99-0.99) P < 0.001 
 N % N % OR (95% CI) P value  
Severe depression 910 39.5 3,090 24.4 1.89 (1.72-2.08) P < 0.001 
Recurrent depression  1,583 74.9 6,786 55.8    2.26 (2.04-2.52) P < 0.001 
Duration of worst episode       
<1 month 76 3.3 654 5.2 Ref  
1 to 3 months 436 19.0 3,347 26.6 1.14(0.88-1.46) P < 0.05 
3 to 6 months 440 19.2 2,693 21.4 1.43(1.10-1.85) P < 0.001 
6 to 12 months 434 18.9 2,600 20.7 1.47(1.14-1.91) P < 0.001 
1 to 2 years 352 15.4 1,864 14.8 1.74(1.33-2.27) P < 0.001 
>2 years 554 24.2 1,410 11.2 3.56(2.74-4.61) P < 0.001 
Help seeking for depression 2,076 90.1 10,387 82.2 1.94(1.67-2.25) P < 0.001 
Note: Models are adjusted for age and gender 
Supplementary Table 3. Differences in lifestyle factors and adverse life events between persons with 
atypical depression versus depression with typical neurovegetative symptoms 
  Atypical Depression Typical Depression   
  N=2,305  N=12,660    
Lifestyle factors 
 
n % n % OR (95% CI) P value  
Smoking          
 
Never 
Ever 
 
1,117 
 
48.7 
 
5,962 
 
47.2 
Ref 
1.11(1.01-1.21) 
 
 
P < 0.05 
Social isolation     
 
No 
Yes 
 
293 
 
12.9 
 
1,233 
 
9.8 
Ref 
1.37(1.20-1.58) 
 
P < 0.001 
Loneliness No 
Yes 
 
223 
 
10.1 
 
668 
 
5.4 
Ref 
1.74(1.50-2.01) 
 
P < 0.001 
Moderate physical 
activity 
No 
Yes 
 
1,312 
 
56.9 
 
8,244 
 
65.1 
Ref 
0.80(0.74-0.88) 
 
P < 0.001 
Childhood adversities 
      
Felt loved  Yes 
No 
 
378 
 
16.5 
 
1,311 
 
10.4 
Ref 
1.66 (1.46-1.88) 
 
P < 0.001 
Felt hated  No 
Yes 
 
645 
 
28.1 
 
2,205 
 
17.5 
Ref 
1.72(1.55-1.91) 
 
P < 0.001 
Physical abuse  No  
Yes 
 
449 
 
19.6 
 
1,762 
 
13.9 
Ref 
1.40(1.25-1.57) 
 
P < 0.001 
Sexual abuse No 
Yes 
 
251 
 
11.2 
 
971 
 
7.8 
Ref 
1.42(1.22-1.65) 
 
P < 0.001 
Had someone to take 
to doctor when 
needed as a child 
Yes 
No 
 
263 
 
11.5 
 
1,021 
 
8.1 
Ref 
1.50(1.-1.73) 
 
P < 0.001 
Adulthood adversities       
Been in confiding 
relationship  
Yes 
No 
 
450 
 
19.9 
 
1,799 
 
14.5 
Ref 
1.47(1.31-1.65) 
 
P < 0.001 
 
Physical violence by 
(ex)partner 
No 
Yes 
 
394 
 
17.2 
 
1,641 
 
 
13.0 
Ref 
1.33(1.18-1.50) 
 
P < 0.001 
Belittlement by 
(ex)partner 
No  
Yes 
 
837 
 
36.5 
 
3,562 
 
28.2 
Ref 
1.41(1.28-1.55) 
 
P < 0.001 
Non-consensual 
sexual interference 
by (ex)partner 
No 
Yes 
 
201 
 
8.8 
 
744 
 
5.9 
Ref 
1.49(1.26-1.75) 
 
P < 0.001 
 
Unable to pay rent or 
mortgage 
No 
Yes 
 
317 
 
13.9 
 
1,226 
 
9.8 
Ref 
1.46(1.28-1.67) 
 
P < 0.001 
Catastrophic 
trauma 
No 
Yes 
 
1,562 
 
67.8 
 
7,232 
 
57.1 
Ref 
1.56(1.42-1.71) 
 
P < 0.001 
Note: Models are adjusted for age and gender. Catastrophic trauma is defined being attacked, mugged, robbed,  
exposed to violent crime, sexual assault, serious accidents, life-threatening illness, combat or war, violent death. 
  
Supplementary Table 4. Differences in psychiatric and physical comorbidities between persons 
with atypical depression versus depression with typical neurovegetative symptoms 
 
 Atypical Depression Typical Depression   
 N=2,305  N=12,660    
Probable psychiatric diagnoses based on self-reported symptoms    
 n % n % OR (95% CI) P value 
Wider Bipolar 166 7.4 536 4.3 1.66(1.39-2.00) P < 0.001 
Bipolar I 118 5.3 324 2.6 1.94(1.56-2.42) P < 0.001 
Bipolar II 38 1.7 154 1.2 1.32(1.92-1.89) P = 0.13 
GAD 754 60.2 2,884 45.9 1.70(1.50-1.93) P < 0.001 
PTSD 717 31.3 1,970 15.6 2.28(2.06-2.53) P < 0.001 
Self-reported psychiatric diagnoses      
Schizophrenia 14 0.6 25 0.2 2.79(1.43-5.44) P < 0.01 
Other psychosis 50 2.2 140 1.1 1.90(1.37-2.65) P < 0.001 
Panic attacks 413 17.9 1,663 13.1 1.43(1.27-1.61) P < 0.001 
Agoraphobia 40 1.7 119 0.9 1.93(1.34-2.79) P < 0.001 
Social phobia 135 5.9 338 2.7 2.12(1.72-2.61) P < 0.001 
Any other phobia 83 3.6 263 2.1 1.81(1.41-2.33) P < 0.001 
OCD 75 3.3 164 1.3 2.32(1.76-3.07) P < 0.001 
Anorexia nervosa 18 0.8 243 1.9 0.38(0.23-0.61) P < 0.001 
Bulimia nervosa 24 1.0 105 0.8 1.02(0.65-1.61) P = 0.90 
Binge-eating 116 5.0 64 0.5 10.06(7.36-13.75) P < 0.001 
ADHD 10 0.4 19 0.2 2.65(1.22-5.77) P < 0.05 
Autism spectrum disorder 16 0.7 21 0.2 3.43(1.77-6.64) P < 0.001 
Personality disorder 27 1.2 88 0.7 1.49(0.96-2.31) P = 0.07 
Any addiction 360 16.3 1,222 9.9 1.65(1.45-1.88) P < 0.001 
Substance Dependence 232 10.7 759 6.00 1.65(1.41-1.93) P < 0.001 
Alcohol Dependence 61 2.7 178 1.4 1.79(1.32-2.42) P < 0.001 
Self-harm 385 16.8 1,397 11.1 1.47(1.30-1.67) P < 0.001 
Suicidal intention among 219 59.5 801 59.8 1.04(0.82-1.32) P = 0.21 
self-harmers       
Physical comorbidities       
Any long-standing illness 1,169 50.7 4,032 32.5 2.46(2.25-2.70) P < 0.001 
CVD 650 28.3 2,608 20.6 1.92(1.72-2.13) P < 0.001 
Metabolic syndrome 194 8.4 401 3.2 3.48(2.90-4.18) P < 0.001 
Body Mass Index (kg/m2)       
Normal (< 18.5) 334 14.5 5,909 46.8 Ref.  
Underweight (18.5–24.9) 3 0.1 116 0.9 0.44(0.14-1.40) P = 0.16 
Overweight (25.0–29.9) 834 36.2 4,614 36.5 3.58(3.13-4.10) P < 0.001 
Obese (>30) 1,131 49.1 1,998 15.8 11.34(9.91-12.99) P <0.001  
Note: Models are adjusted for age and gender 
  
  
Supplementary Table 5. Tetrachoric correlations between individual depressive symptoms among persons with lifetime probable MDD 
 Weight gain Hypersomnia Weight loss Hyposomnia Concentration Tiredness Interest loss Sadness Worthlessness Death thoughts 
Weight gain 1.00 
         Hypersomnia 0.20*** 1.00 
        Weight loss N/A -0.20*** 1.00 
       Hyposomnia 0.06*** N/A -0.14*** 1.00 
      Concentration  -0.04* 0.07*** -0.04* -0.09*** 1.00 
     Tiredness 0.21*** 0.34*** -0.18*** 0.01 0.22*** 1.00 
    Interest loss 0.06*** 0.26*** -0.08*** 0.04** 0.07*** 0.13*** 1.00 
   Sadness -0.08** 0.02 -0.06* -0.02 0.01 -0.13* N/A 1.00 
  Worthlessness 0.13*** 0.20*** -0.16*** 0.02* 0.15*** 0.09*** 0.17*** 0.21*** 1.00 
 Death thoughts 0.01 0.04*** 0.02* -0.08*** 0.01 -0.08*** 0.03* 0.07** 0.14*** 1.00 
* p < 0.05; ** p < 0.01; ***p < 0.001; the correlation between sadness and interest loss could not be computed because there are no depressed persons with a score of zero on 
both sadness and interest loss given that the MDD criteria require the presence of at least one of the two symptoms. 
Supplementary Table 6: Question and Answer Format of the UK Biobank Mental Health Questionnaire 
 
Variable  Question Asked Possible Answers 
Sociodemographic factors    
    
Age  Please confirm your month & year of mm yyyy 
  birth   
Gender  Please confirm your sex 0 = Female 
   1 = Male 
     
Education  Which of the following qualifications 0 = None of the above 
  do you have? 1 = Other 
   2 = GCSE 
   3 = A Level 
   4 = Degree 
     
Income  What is the average total income 0 = <£18,000 
  before tax received by your household? 1 = £18,000-30,000 
   2 = £30,000-52,000 
   3 = £52,000-100,000 
   4 = >£100,000 
   UN = Do not know 
   DA = Prefer not to answer 
    
House ownership  Do you own or rent the 1= Rent social 
  accommodation that you live in? 2 = Rent private 
   3 = Own mortgage 
   4 = Own outright 
   UN = Do not know 
   DA = Prefer not to answer 
Risk factors and life events    
    
Smoking  Do you smoke tobacco now? (i.e., 0 = No 
  during the baseline UKB assessments) 1 = Yes, on most or all days 
   2 = Only occasionally 
   3 = Prefer not to answer 
  In the past, how often have you 0 = I have never smoked 
  smoked tobacco? 1 = Just tried once or twice 
   2 = Smoked occasionally 
   3 = Smoked on most or all days 
   4 = Prefer not to answer 
   A binary variable was derived for 
   smoking status: 
   0 = Never smoked, if current smoker = 0 
   and past smoker < 2; 
   1 = Ever smoker, if current smoker = 1 
   and/or past smoker > 1 
    
Moderate physical  In a typical week, on how many days A binary variable was generated: 
activity  did you do 10 minutes of moderate 1 = 10 minutes of moderate physical 
  physical activities like carrying light activities at least 3 days a week; 
  loads, cycling at normal pace? (do not 0 = 10 minutes of moderate physical 
  include walking) activities less than 3 days a week; 
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Social isolation (1) “Including yourself, how many 1 point for living alone 
 people are living together in your   
 household? Include those who usually   
 live in the house such as students living   
 away from home during term time,   
 partners in the armed forces or   
 professions such as pilots”;   
 (2) “How often do you visit friends or 1 point for friends and family visit less 
 family or have them visit you? than once a month 
 (3) “Which of the following 1 point for no participation in social 
 [leisure/social activities] do you engage activities at least weekly 
 in once a week or more often?”.   
  Total score 0=3 
  A binary variable was derived: 
  0 = no social isolation, if total score ≤ 1 
  1 = social isolation, if total score ≥ 2 
Loneliness (1) “Do you often feel lonely?” 0 = No 
  1 = Yes 
 (2) “How often are you able to confide 0 = almost daily to once every few 
 in someone close to you?” months 
  1 = never or almost never 
 Elovainio, M., C. Hakulinen, et al. A binary variable was derived. 
 "Contribution of risk factors to excess Lonely|: total score = 2 
 mortality in isolated and lonely Not lonely|: total score < 2 
 individuals: an analysis of data from   
 the UK Biobank cohort study." The   
 Lancet Public Health 2: e260-e266.   
    
Childhood adverse Includes 1 question from each domain 0 = Never true 
events of the Childhood Trauma 1 = Rarely true 
 Questionnaire. 2 = Sometimes true 
  3 = Often 
 Walker, E. A., et al. (1999). "Adult 4 = Very often true 
 health status of women with histories of DA = Prefer not to answer 
 childhood abuse and neglect." The   
 American Journal of Medicine 107(4): Binary variables were derived based on 
 332-339 the following thresholds: 
  20489 Felt loved as a child < 2 
  OR 
  20488 Physically abused by family as a 
  child ≥2 
  OR 
  20487 Felt hated by family member as a 
  child ≥2 
  OR 
  20490 Sexually molested as a child ≥2 
  OR 
  20491 Someone to take to doctor when 
  needed as a child < 3 
    
Adult adverse events Based on answers to the five questions 0 = Never true 
 of Adult Trauma Screen (written for 1 = Rarely true 
 this questionnaire). 2 = Sometimes true  
 
 
7 
  3 = Often 
  4 = Very often true 
  DA = Prefer not to answer 
  Binary variables were derived based on 
  the following thresholds: 
  20522 Been in a confiding relationship as 
  an adult < 2 
  20523 Physical violence by partner or ex- 
  partner as an adult ≥ 2 
  20521 Belittlement by partner or ex- 
  partner as an adult ≥2 
  20524 Sexual interference by partner or 
  ex-partner without consent as an adult ≥2 
  20525 Able to pay rent/mortgage < 3 
    
Catastrophic trauma In your life, have you: Endorsed one or more events from 
 a) Been a victim of a sexual assault, checklist 
 whether by a stranger or someone you   
 knew? 0 = Never 
 b) Been attacked, mugged, robbed, or 1 = Yes, but not in the last 12 months 
 been the victim of a physically violent 2 = Yes, within the last 12 months 
 crime? DA = Prefer not to answer 
 c) Been in a serious accident that you   
 believed to be life-threatening at the A binary variable was derived 
 time? 0 = Never 
 d) Witnessed a sudden violent death 1 = Ever (experienced 1 or several 
 (eg. murder, suicide, aftermath of an catastrophic events within the last 12 
 accident)? months or before) 
 e) Been diagnosed with a life-   
 threatening illness?   
 f) Been involved in combat or exposed   
 to a war-zone (either in the military or   
 as a civilian)?   
    
Depression Features    
    
Depression age of onset Regarding times in your life when you Record years of age when first felt this 
 have had feelings of depression or loss way 
 of interest: UN = Do not know 
 About how old were you the FIRST DA = Prefer not to answer 
 time you had a period of two weeks   
 like this? (Whether or not you received   
 any help for it.)   
   
Severe depression Meets criteria for a lifetime diagnosis A binary variable was derived: 
 of MDD (see Depression Ever below) 1 = severe MDD 
 and reports all 8/8 symptoms of 0 = non-severe MDD 
 depression assessed with CIDI-SF and   
 reports a lot of impairment.   
   
Recurrent depression Regarding times in your life when you Text box for number. 
 have had feelings of depression or loss 1 = single depression episode 
 of interest: 2 and above = recurrent depression 
 How many periods did you have in episodes 
 your life lasting two or more weeks   
 where you felt like this?   
    
Depression duration Please think of the two-week period in 1 = less than a month 
 your life when your feelings of 2 = between one and three months  
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 depression or loss of interest were 3 = over three months, but less than six 
 worst. About how long did you feel months 
 this way? 4 = over six months, but less than 12 
  months 
  5 = one to two years 
  6 = over two years 
Help seeking for Regarding times in your life when you 0 = No 
depression have had feelings of depression or loss 1 = Yes 
 of interest: UN = Do not know 
 Did you ever tell a professional about DA = Prefer not to answer 
 these problems (medical doctor,   
 psychologist, social worker, counsellor,   
 nurse, clergy, or other helping   
 professional)   
    
Psychiatric comorbidities based on self-reported diagnoses   
    
Clinical diagnoses Have you been diagnosed with one or [Select up to seven from] 
based on self–reports more of the following mental health 0 = None of the above 
(A) problems by a professional, even if you 1 = Depression 
 don’t have it currently? (tick all that 2 = Mania, hypomania, bipolar or manic- 
 apply): depression 
  3 = Anxiety, nerves or generalized 
 By professional we mean: any doctor, anxiety disorder 
 nurse or person with specialist training 4 = Social anxiety or social phobia 
 (such as a psychologist or therapist). 5 = Agoraphobia 
  6 = Any other phobia (e.g. disabling fear 
 Please include disorders even if you of heights or spiders 
 did not need treatment for them or if 7 = Panic attacks 
 you did not agree with the diagnosis 8 = Obsessive compulsive disorder 
  (OCD) 
  DA = Prefer not to answer 
   
Clinical diagnoses Have you been diagnosed with one or [Select up to eight from] 
based on self–reports more of the following; mental health 0 = None of the above 
(B) problems by a professional, even if you 1 = Anorexia nervosa 
 don’t have it currently? (tick all that 2 = Bulimia nervosa 
 apply): 3 = Psychological over-eating or binge- 
  eating 
 By professional we mean: any doctor, 4 = Schizophrenia 
 nurse or person with specialist training 5 = Any other type of psychosis or 
 (such as a psychologist or therapist). psychotic illness 
 Please include disorders even if you 6 = A personality disorder 
 did not need treatment for them or if 7 = Autism, Asperger’s or autistic 
 you did not agree with the diagnosis. spectrum disorder 
  8 = Attention deficit or attention deficit 
  and hyperactivity disorder (ADD/ADHD) 
  DA = Prefer not to answer 
    
Any addiction Have you ever been addicted to or 1 = Yes 
 dependent on one or more things, 0 = No 
 including substances (not UN = Do not know 
 cigarettes/coffee) or behaviors (such as DA = Prefer not to answer 
 gambling)?   
    
Substance Dependence: Have you been addicted to or 1 = Yes 
 dependent on prescription or over-the- 0 = No 
 counter medication? UN = Do not know 
  DA = Prefer not to answer 
 Have you been addicted to illicit or 1 = Yes 
 recreational drugs? 0 = No  
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  UN = Do not know 
  DA = Prefer not to answer 
  Note: Substance dependence is a 
  subcategory of any addiction 
    
Alcohol Dependence: Have you been physically dependent 1 = Yes 
 on alcohol? 0 = No 
 This means experiencing withdrawal UN = Do not know 
 symptoms, such as sweating, shaking DA = Prefer not to answer 
 and nausea, if you didn’t drink.   
  Note: Alcohol dependence is a 
  subcategory of substance dependence 
    
Self-harm behaviours Have you contemplated harming 0 = No 
 yourself (for example by cutting, 1 = Yes, once 
 biting, hitting yourself or taking an 2 = Yes, more than once 
 overdose)? DA = Prefer not to answer 
 Have you deliberately harmed yourself, 0 = No 
 whether or not you meant to end your 1 = Yes 
 life? DA = Prefer not to answer 
    
Self-harm with suicide Have you harmed yourself with the 0 = No 
attempt intention to end your life? 1 = Yes 
  DA = Prefer not to answer 
    
Physical comorbidities    
    
Long-standing illness Do you have any long-standing illness, 0 = No 
 disability or infirmity? 1 = Yes 
  UN = Do not know 
  DA = Prefer not to answer 
    
Metabolic syndrome Participants were classified as having   
 metabolic syndrome if:   
 -   Their waist circumference was:   
 ≥ 102 cm for males and   
 ≥ 88 cm for females;   
 -   They had any two of the   
 following: diabetes, hypertension,   
 hypercholesterolemia.   
    
Diabetes Q1: Has a doctor ever told you that 0 = No 
 you have diabetes? 1 = Yes 
  UN = Do not know 
  DA = Prefer not to answer 
 Q2: Do you regularly take any of the 1 = cholesterol lowering medication 
 following medications? (you can select 2 = blood pressure medication 
 more than one answer) 3 = insulin 
  UN = Do not know 
  DA = Prefer not to answer 
  Participants were considered as diabetes 
  cases if they answered 
  Q1 = 1 and/or Q2 = 3. 
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Hypertension Q1: Has a doctor ever told you that 0 = No 
 you have high blood pressure? 1 = Yes 
  UN = Do not know 
  DA = Prefer not to answer 
 Q2: Do you regularly take any of the 1 = cholesterol lowering medication 
 following medications? (you can select 2 = blood pressure medication 
 more than one answer) 3 = insulin 
  UN = Do not know 
  DA = Prefer not to answer 
  Participants were considered as 
  hypertension cases if they answered 
  Q1 = 1 and/or Q2 = 2. 
    
Hypercholesterolemia Q1: Has a doctor ever told you that 0 = No 
 you have hypercholesterolemia 1 = Yes 
  UN = Do not know 
 Q2: Do you regularly take any of the DA = Prefer not to answer 
 following medications? (you can select   
 more than one answer) 1 = cholesterol lowering medication 
  2 = blood pressure medication 
  3 = insulin 
  UN = Do not know 
  DA = Prefer not to answer 
  Participants were considered as 
  hypertension cases if they answered 
  Q1 = 1 and/or Q2 = 1. 
    
Cardiovascular disease Has a doctor ever told you that you 1 = Heart attack 
 have had any of the following 2 = Angina 
 conditions? (You can select more than 3 = Stroke 
 one answer) 4 = High blood pressure 
  0 = None of the above 
  DA = Prefer not to answer 
  A binary variable was derived: 
  0 = None 
  1 = any of the above 
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Supplementary Table 7. Case and control criteria derived from the UK Biobank Mental Health 
Questionnaire 
 
Disorder - case and control Fields and codes Notes and references 
definitions   
   
Case: Lifetime depression At least one core symptom of  
 depression, most or all of the day on CIDI-SF (Composite International 
 most or all days for a two-week Diagnostic Interview – Short Form), 
 period, with at least five depressive depression module, lifetime version. 
 symptoms that represent a change Scored based on DSM definition of 
 from usual occurring over the same major depressive disorder 
 time-scale, with some or a lot of  
 impairment. Kessler RC, Andrews G, Mroczek D, 
 Persistent sadness (20446) = Yes OR Ustun B, Wittchen HU (1998). The 
 Loss of interest (20441) = Yes World Health Organization composite 
 AND international diagnostic interview 
 How much of day (20436) = Most of 
short‐ form (CIDI‐ SF). Int J Methods 
 day or All day long Psychiatr Res, 7(4):171-85. 
 AND  
 Did you feel this way (20439) =  
 Almost every day or Every day AND  
 Impairment (20440) = Somewhat or A  
 lot  
 AND  
 Total number of symptoms endorsed  
 (core and others) >= 5  
 Persistent sadness (core) 20446; Loss  
 of interest (core) 20441; Tired or low  
 energy 20449; Gain or loss of weight  
 20536 = Gain, Loss or Gain and loss;  
 Sleep change 20532; Trouble  
 concentrating 20435; Feeling  
 worthless 20450; Thinking about  
 death 20437  
   
Control: Lifetime Not endorsing depression or screening Case plus control plus subthreshold 
depression positive on PHQ or CIDI should include all participants with 
 NOT (reported diagnosis of depression valid responses. By excluding 
 20544 or 20002) subthreshold symptoms, we can be 
 AND confident that this group has not 
 NOT Core symptoms from above experienced a classical depressive 
 AND episode 
 PHQ score ≤5  
   
Case: Lifetime bipolar Ever manic/hyper or irritable, plus at Case for depression is not required in 
disorder type I: least three other features (four if never DSM-IV diagnostic criteria, but it is 
 manic/hyper), plus duration a week or added here to improve the positive 
 more, plus symptoms caused predictive value of the test (see text 
 significant problems. Requires also to and references). This definition does 
 be case for depression ever. not exclude antidepressant-induced 
 Case {depression ever} mania. 
 AND  
 High/Hyper 20501 = 01 OR Irritable Cerimele et al. (2014). The prevalence 
 20502 = 01 of bipolar disorder in primary care 
 AND samples: a systematic review, General 
 Four features from: Hospital Psychiatry 36: 19-25 
   High/Hyper 20501; Active  
 20548(01); Talkative Carvalho, A. F., Y. Takwoingi, et al. 
 20548(02); Less sleep (2015). "Screening for bipolar 
 20548(03); Creative/ideas spectrum disorders: a comprehensive 
 20548(04); Restless  
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 20548(5); Confident meta-analysis of accuracy studies." 
 20548(55); Thoughts racing Journal of affective disorders 172: 
 20548(7); Easily distracted 337-346 
 20548(8)  
 AND  
 Duration 20492 = A week or more  
 AND  
 Symptoms caused problem 20493 =  
 yes  
   
Variant: Lifetime bipolar As above, without disruption from There is less agreement over the 
type II: symptoms definition of bipolar affective disorder 
 Case {depression ever} type II. DSM-IV criteria require 
 AND symptoms for four days or more. Here 
 High/Hyper 20501 = 01 OR Irritable is one week, so could be predicted to 
 20502 = 01 miss some cases. 
 AND  
 Four features as above  
 AND  
 Duration 20492 = A week or more  
   
Control: Hypomania / NOT {hypomania/mania} AND NOT  
Mania {categorised bipolar on last UKB  
 categorisation 20126 = 1 or 2} AND  
 NOT {self-reported bipolar  
 20544=10}  
   
Case: Lifetime GAD Excessive worrying about a number of CIDI-SF (Composite International 
 issues, occurring most days for six Diagnostic Interview – Short Form), 
 months and difficult to control, with GAD module, lifetime version. Scored 
 three or more somatic symptoms and based on DSM definition of GAD 
 functional impairment.  
 Worried tense of anxious (20421) = Kessler RC, Andrews G, Mroczek D, 
 Yes Ustun B, Wittchen HU. The World 
 AND Health Organization composite 
 Duration (20420) >= 6 months or All international diagnostic interview 
 my life 
short‐ form (CIDI‐ SF). Int J Methods 
 AND Psychiatr Res. 1998;7(4):171-85. 
 Most days (20538) = Yes  
 AND National Institute for Health and 
 Excessive: More than most (20425) Clinical Excellence. Generalised 
 OR Stronger than most (20542) anxiety disorder and panic disorder in 
 AND adults: management. NICE Clinical 
 Number of issues: More than one Guideline CG113 (available at 
 thing (20543) OR Different worries https://www.nice.org.uk/guidance/cg1 
 (20540) 13) 2011 
 AND  
 Difficult to control: Difficult to stop  
 worrying (20541) OR Couldn’t put it  
 out of mind (20539) OR Difficult to  
 control (20537)  
 AND  
 Functional impairment: Role  
 interference (20418) = Some or A lot  
 AND  
 3 somatic symptoms out of:  
 Restless. 20426; Keyed up or  
 on edge. 20423; Easily tired.  
 20429; Having difficulty  
 keeping your mind on what  
 you were doing. 20419; More  
  13  
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 irritable than usual. 20422;  
 Having tense, sore, or aching  
 muscles. 20417; Often having  
 trouble falling or staying  
 asleep. 20427  
   
Control: Lifetime GAD Not meeting criteria for GAD ever nor Excluding those that screen positive 
 scoring over low cut-off for GAD-7 for mild anxiety means that there is 
 NOT case {GAD ever} greater confidence that this group have 
 AND not had anxiety disorder 
 GAD-7 score < 5  
   
Case: Current PTSD Case: PCL-6 sum of scores ≥ 14 Does not currently require catastrophic 
  trauma, but it refers to “stressful 
 Sum of scores on questions event” in the text of the questions as 
 representing the core symptoms of this is not an exhaustive list of 
 PTSD (scored 1-5) possible traumatic events. 
 {20497Repeated disturbing thoughts  
 of stressful experience in past month Using PHQ item for concentration, 
 20498Felt very upset when reminded scores out of 29 (conventionally 
 of stressful experience in past month scores out of 30), and will make it 
 20495Avoided activities or situations slightly harder to reach conventional 
 because of previous stressful threshold. 
 experience in past month  
 20496Felt distant from other people in Lang AJ, Stein MB (2005).An 
 past month abbreviated PTSD checklist for use as 
 20494Felt irritable or had angry a screening instrument in primary 
 outbursts in past month} care. Behaviour Research and 
 + 20508 Trouble concentrating Therapy,43(5):585-94 
 (scored 1-4)  
 (nb biobank coded 0-4, subtract 5 to  
 adjust)  
   
Control: Current PTSD PCL-6 sum of scores 13 or less. Note: “Current” PTSD refers to 
  persons meeting the criteria for PTSD 
  when completing the MHQ 
  assessments. 
    
 
 
 
 
 
 
 
 
 
 
 
